


# NASH DRUG DEVELOPMENT

A COMPETITIVE EDGE FOR NASH STUDIES

## INTEGRATED NASH EXPERTISE



## IMAGING CORE LABORATORY

MR- AND ULTRASOUND-BASED BIOMARKERS FOR NASH STUDIES

- QUANTITATIVE VOLUMETRIC IMAGING (MRI)
- PROTON DENSITY FAT FRACTION (MRI-PDFF)
- ELASTOGRAPHY (MRE)
- SPECTROSCOPY (MRS)
- VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY +/- CONTROLLED ATTENUATION PARAMETER (VCTE+/-CAP)

## STRATEGIC EXECUTION

EXPERTISE IN MANAGING NASH STUDIES

- IN-HOUSE PHYSICIANS
- OPERATIONAL TEAMS
- GLOBAL REGULATORY

## GLOBAL EXPERIENCE

EXPERIENCED IN MANAGING NASH TRIALS FOR OVER NINE YEARS



## CENTRAL LAB CAPABILITIES

NASH BIOMARKER STRATEGIC SERVICES

- CYTOKERATIN –18 (M30 AND M65)
- APOLIPOPROTEIN A1
- APOLIPOPROTEIN B
- LEPTIN
- ADINOPONECTIN
- RESISTIN
- FREE FATTY ACIDS
- GHRELIN
- hsCRP
- INTERLEUKIN-6
- TNF $\alpha$
- TIMP-1, HA, P3NP